Nervonik Raises $13 Million to Advance Next-Generation Peripheral Nerve Stimulation for Chronic Pain Relief

California-based Nervonik has closed a $13 million Series A funding round led by U.S. Venture Partners (USVP), with participation from Foothill Ventures, Correlation Ventures, and other investors. The funding will advance clinical studies, accelerate regulatory clearance, and prepare for commercialization efforts aimed at transforming chronic pain treatment.

This funding builds on Nervonik’s earlier $4.4 million in SAFE and convertible note financings from Shangbay Capital, Camford Capital, Joyance Partners, Life Science Angels, Seraph Group, and other investors.

Nervonik recently completed its first-in-human clinical study, demonstrating the potential of its peripheral nerve stimulation (PNS) technology to transform chronic pain treatment. The company’s proprietary wirelessly powered PNS technology delivers minimally invasive, patient-friendly therapy for personalized pain relief. With chronic pain affecting over 50 million people in the U.S. alone, Nervonik’s opioid-free PNS technology offers a compelling alternative to traditional pain management methods, targeting a multibillion-dollar market opportunity.

“We are excited to receive this strong support from top institutional investors as we push forward in advancing peripheral nerve stimulation technology,” said Aydin Babakhani, PhD, founder and CEO of Nervonik. “This financing advances our mission to bring a novel solution to millions of people suffering from chronic pain.”